A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) (UNCOVER-3). We report two studies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specifically targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis. A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) (UNCOVER-2). This study is ongoing, but not recruiting participants. Sponsor:.
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2). Gov Tue 01 May 2012 This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis. Experimental: 80 mg ixekizumab Dosing Regimen 2 – Experimental: 80 mg ixekizumab Dosing Regimen 3 – Active Comparator: 50 mg etanercept – Placebo Comparator: Placebo. P19 subunit of IL-23. Phase II. Guselkumab (CNTO 1959). Janssen. The final drug dose was given on week 40, and the participants were followed until week 72. Two phase III studies for moderate-to-severe plaque psoriasis with 80 mg doses given every 2 or 4 weeks show a 77. Psoriasis Clinical Insight Studies: Secukinumab, Ixekizumab, and Apremilast. Secukinumab treats symptoms of moderate-to-severe plaque psoriasis in certain adults. The study was published in the International Journal of Dermatology entitled Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. The participants in UNCOVER-2 and UNCOVER-3 also received 50 mg of a drug, known as etanercept, which treats autoimmune diseases.
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2). Status: Active, not recruiting. Study Phase: Phase 3. Start Date: May 2012 Completion Date: July 2019. Recently published results from the Phase 3 ELOQUENT-2 study (NCT01239797) indicated that patients with relapsed or refractory multiple myeloma who received elotuzumab in combination with lenalidomide and dexamethasone had a significant relative reduction in the risk of disease progression or death. Of these studies, only the OAK study (NCT02008227), a Phase 3 study of atezolizumab compared to docetaxel in patients with locally advanced or metastatic NSCLC who failed platinum therapy, is active but not recruiting participants. An individualised approach to treatment is mandatory.1 Psoriasis affects 2. This approach allows dose reduction for relatively aggressive systemic or photo therapy,2 both of which have more severe, and often dose-limiting, side effects. A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) NCT01597245.
Nct01597245 A Phase 3 Study In Participants With
Eli Lilly and Company has registered success in phase-three trials in which effect of ixekizumab was assessed as a treatment for moderate-to-severe plaque psoriasis. The UNCOVER-2 and UNCOVER-3 are double-blind, multicenter, phase-three studies in which more than 2,500 patients with moderate-to-severe plaque psoriasis from 19 nations were included. In the studies, the participants were either asked to take a placebo, etanercept (50 mg twice a week) or ixekizumab (80 mg every two or four weeks) for 12 weeks following a 160-mg dose. OBJECTIVE: This phase 2, dose-ranging clinical study investigated the efficacy and safety of IngMeb in larger areas on trunk and extremities in patients with AK (NCT01998984). OBJECTIVE: To evaluate differences in patient reported outcomes (PROs) among individuals who achieve PASI 100 compared to those with lower treatment responses in patients with psoriasis participating in a trial of ixekizumab, an anti- IL-17A monoclonal antibody. Both Phase II and III clinical trials have demonstrated the effectiveness of secukinumab in the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and noninfectious uveitis. In this study, 125 psoriasis patients were recruited at multiple centers. Boehringer Ingelheim has released results of a phase II study of BI 655066 compared to ustekinumab for moderate-to-severe plaque psoriasis. LILLY’S IXEKIZUMAB FOUND TO BE EFFECTIVE IN PHASE III PSORIASIS STUDIES. In the two active comparator studies (UNCOVER-2 and 3), patients could be assigned to receive etanercept 50mg twice weekly for 12 weeks. Writing in Arthritis Care and Research, the 16 participants in the 2013 Psoriatic Arthritis Forum outlined three priority actions:. A Phase II clinical study to assess the safety and efficacy of CF101 for the treatment of patients with moderate to severe plaque psoriasis was conducted after we already had data from Phase II studies conducted in patients with rheumatoid arthritis showing that CF101 is very safe and has a marked anti-inflammatory effect. A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2). Verified by: Eli Lilly and Company, May 2015.
A Phase 3 Study In Participants With Moderate To Severe Psoriasis (uncover-2)
Psoriasis is a serious, chronic disease that can also have a significant, and sometimes debilitating, psychological and social impact, said Andrew Hotchkiss, President for Lilly Bio-Medicines in Europe and Canada. A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-1). Psoriasis is a chronic, immune disease that affects the skin.2 Psoriasis affects approximately 7. 6 This clinical program included three double-blind, multicenter, Phase 3 studies-UNCOVER-1, UNCOVER-2 and UNCOVER-3-which demonstrated the safety and efficacy of Taltz in patients with moderate-to-severe plaque psoriasis.